Education
About Us
Working with TipRanks
Follow Us
Cellectis SA (FR:ALCLS)
:ALCLS
Top Page
Cellectis SA
(OTC:ALCLS)
Rating:58Neutral
Price Target:
€1.50
▲( 11.94% Upside)
Cellectis SA (ALCLS) vs. iShares MSCI France ETF (EWQ)
Market Cap
€102.08M
Dividend YieldN/A
Average Volume (3M)110.79K
Price to Earnings (P/E)―
Beta (1Y)2.45
Revenue Growth833.95%
EPS Growth38.17%
CountryFR
Employees216
SectorHealthcare
Sector Strength42
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.16
Shares Outstanding72,093,636
10 Day Avg. Volume69,149
30 Day Avg. Volume110,786
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)0.90
Price to Sales (P/S)0.00
P/FCF Ratio5.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Cellectis SA Business Overview & Revenue Model
Company DescriptionCellectis SA is a biotechnology company specializing in the development of gene-editing technologies for therapeutic applications. Based in France, the company focuses on using its proprietary TALEN technology to develop innovative treatments in the areas of oncology and genetic diseases. Cellectis aims to leverage its expertise in gene editing to create next-generation gene-modified cell therapies.
How the Company Makes MoneyCellectis makes money primarily through the development and commercialization of its gene-editing technologies and therapies. The company generates revenue through strategic partnerships, licensing agreements, and collaborations with other pharmaceutical and biotechnology companies. These partnerships typically involve upfront payments, milestone payments, and royalties on sales of products that utilize Cellectis's technology. Additionally, Cellectis may receive funding from grants and research contracts to support its innovative research and development efforts.
Cellectis SA Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 41.51M | 755.00K | 19.17M | 73.95M | 73.95M | Gross Profit |
| 41.51M | 18.00K | 17.40M | 37.67M | 37.67M | EBIT |
| -59.55M | -97.30M | -89.67M | -85.44M | -85.44M | EBITDA |
| -9.46M | -92.64M | -76.38M | -85.44M | -43.34M | Net Income Common Stockholders |
| -36.76M | -101.06M | -98.69M | -86.28M | -72.57M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 260.31M | 203.81M | 97.70M | 186.13M | 268.24M | Total Assets |
| 383.54M | 334.27M | 261.22M | 382.08M | 469.47M | Total Debt |
| 91.46M | 85.06M | 82.85M | 102.24M | 111.30M | Net Debt |
| -51.79M | -51.65M | -14.85M | -83.90M | -156.94M | Total Liabilities |
| 252.51M | 249.57M | 135.28M | 145.60M | 160.63M | Stockholders Equity |
| 131.03M | 84.69M | 117.97M | 221.29M | 275.57M |
| Cash Flow | Free Cash Flow | |||
| 19.15M | -25.82M | -89.89M | -124.31M | -126.52M | Operating Cash Flow |
| 22.99M | -24.75M | -87.44M | -104.56M | -80.26M | Investing Cash Flow |
| -102.81M | -15.51M | -2.76M | 7.28M | -54.34M | Financing Cash Flow |
| 89.11M | 82.86M | 1.15M | 47.52M | 27.32M |
Cellectis SA Technical Analysis
Negative
1.34
Price Trends
1.30
Positive
1.42
Negative
1.63
Negative
Market Momentum
<0.01
Positive
48.80
Neutral
30.25
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALCLS, the sentiment is Negative. The current price of 1.34 is below the 20-day moving average (MA) of 1.38, above the 50-day MA of 1.30, and below the 200-day MA of 1.63, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 48.80 is Neutral, neither overbought nor oversold. The STOCH value of 30.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALCLS.
Cellectis SA Peers Comparison
Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Performance Comparison
FR:ALCLS
Cellectis SA
1.42
-1.08
-43.36%
FR:VLA
Valneva
2.78
-1.15
-29.23%
Cellectis SA Earnings Call Summary
Earnings Call Date:May 12, 2025
(Q4-2024)
| % Change Since: -0.74%|
Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment Positive
The earnings call was largely positive, highlighting strategic collaboration, financial stability, and progress in clinical programs. However, challenges in ongoing arbitration and regulatory uncertainties were noted, but they did not overshadow the advancements and strategic gains made by the company.Q4-2024 Updates
Positive Updates
Strategic Collaboration with AstraZeneca
Cellectis announced the start of R&D activities for three programs under their collaboration with AstraZeneca, including allogeneic CAR T for hematological malignancies, solid tumors, and an in vivo gene therapy. AstraZeneca completed an additional equity investment of $140 million, owning approximately 44% of Cellectis' share capital.
Financial Strength and Cash Runway
Cellectis' cash, cash equivalents, restricted cash, and fixed term deposits amounted to $264 million as of December 31, 2024, up from $156 million in 2023. The company is confident that their cash runway will fund operations into mid-2027.
UCART22 and UCART20x22 Progress
Cellectis received Orphan Drug Designation and Rare Pediatric Disease designation for UCART22. The company expects to present Phase 1 data for UCART22 in the third quarter of 2025 and for UCART20x22 in late 2025.
Manufacturing and Innovation
Cellectis showcased promising CAR T strategies targeting solid tumors using TALEN gene editing technology, presenting preclinical data at major conferences and publishing articles in scientific journals.
Negative Updates
Challenges in Servier Arbitration
Cellectis is involved in ongoing arbitration with Servier, limiting the company's ability to comment on potential outcomes.
Regulatory and Market Uncertainties
There are ongoing regulatory interactions required to align on Phase 2 registration strategies for UCART22 and UCART20x22, indicating potential uncertainties in development timelines.
Company Guidance
During the Cellectis Full Year 2024 Earnings Conference Call, the company provided guidance on various metrics, highlighting significant progress and future plans. Cellectis announced the commencement of three programs under their collaboration with AstraZeneca, including allogeneic CAR T programs for hematological malignancies and solid tumors, and an in vivo gene therapy for a genetic disorder. AstraZeneca's additional equity investment of $140 million resulted in them owning approximately 44% of Cellectis' share capital. Cellectis expects to present Phase 1 data for their UCART22 product in Q3 2025, with regulatory discussions planned to align on a Phase 2 strategy. The NATHALI-01 study for UCART20x22 in non-Hodgkin lymphoma continues, with Phase 1 data expected in late 2025. The company's cash position was strengthened, enabling a cash runway until mid-2027, with cash, cash equivalents, and fixed term deposits totaling $264 million as of December 31, 2024. Cellectis emphasized its focus on advancing clinical trials, leveraging its technology, and expanding strategic partnerships to address unmet medical needs.Cellectis SA Corporate Events
Cellectis Reports 2024 Financial Results and Strategic Advances in CAR T-Cell Therapies
Mar 13, 2025
Cellectis has announced its financial results for the fourth quarter and fiscal year 2024, alongside a business update. The company is advancing its clinical trials, particularly UCART22 and UCART20x22, with significant regulatory designations from the FDA and European Commission, enhancing its position in the CAR T-cell therapy market. Its strategic partnership with AstraZeneca, including a $140 million investment, supports the development of next-generation genomic medicines, with a strong cash position projected to last until mid-2027.
Cellectis Advances Clinical Programs and Strengthens AstraZeneca Partnership
Mar 13, 2025
Cellectis has reported its financial results for the fourth quarter and full year 2024, highlighting significant progress in its clinical programs and strategic partnerships. The company is advancing its UCART22 and UCART20x22 programs, with key data readouts expected in 2025. Cellectis has also strengthened its collaboration with AstraZeneca, which includes an additional equity investment of $140 million, ensuring financial stability until mid-2027. The company’s focus remains on developing next-generation genomic medicines to address unmet patient needs.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.